Metastatic breast cancers;Cancer du sein métastatique - Prise en charge différentielle en fonction des caractéristiques clinicopathologiques: Réflexions d'experts sur les facteurs pronostiques, prédictifs d'efficacité et de décision thérapeutique

Oncologie

Volumn 10, Issue 2, 2008, Pages 136-148

  Campone, Mario ^a   Deplanque, Gaël ^b   Dohollou, Nadine ^c   Gligorov, Joseph ^d   Largillier, Rémy ^e   Namer, Moïse ^f   Penault Llorca, Frédérique ^g   Petit, Thierry ^h   Spielmann, Marc ⁱ   Zelek, Laurent ^j  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b SAINT JOSEPH HOSPITAL   (France)

^c Polyclinique de Bordeaux   (France)

^d HÔPITAL TENON   (France)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f Clinique Médicale   (France)

^g CENTRE JEAN PERRIN   (France)

^h CENTRE PAUL STRAUSS   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j AVICENNE HOSPITAL   (France)

more..

Author keywords

Chemotherapy; Hormonotherapy; Metastatic breast cancer; Predictive factors; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; LACTATE DEHYDROGENASE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL DECISION MAKING; FEMALE; HORMONAL THERAPY; HUMAN; METASTASIS; PREDICTOR VARIABLE; PROGNOSIS;

EID: 41549166514     PISSN: 12923818     EISSN: 17652839     Source Type: Journal    
DOI: 10.1007/s10269-008-0838-y     Document Type: Article

References (61)

1. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168
2. 2 in patients with metastatic breast cancer according to the status of anthracycline resistance. J Clin Oncol 19: 336-342
3. Andre F, Hatzis C, Anderson K, et al. (2007) Microtubule-associated protein-Tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 13: 2061-2067
4. Andre F, Pusztai L (2006) Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy. Pharm Res 23: 1951-1958
5. Antoine EC, Campone M, Deplanque G, et al. (2006) Cancer du sein métastatique - Réflexions stratégiques sur la prise en charge de la chimiothérapie de première ligne. Oncologie 8: 1-14
6. Arnould L, Voigt JJ, Bonneterre J, et al. (2003) Epirubicin dose-response effect in node-positive breast cancer patients is independent of HER2 overexpression: 10-year retrospective analysis of French Adjuvant Study Group 05 trial. San Antonio Breast Cancer Symposium: abstract 538
7. Berry DA, Muss HB, Thor AD, et al. (2000) HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 18: 3471-3479
8. Beslija S, Bonneterre J, Burstein H, et al. (2007) Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 18: 215-225
9. Carlomagno C, Perrone F, Gallo C, et al. (1996) c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14: 2702-2708
10. Chang HY, Nuyten DS, Sneddon JB, et al. (2005) Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 102: 3738-3743
11. Chang J, Clark GM, Allred DC, et al. (2003) Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97: 545-553
12. Cristofanilli M, Budd GT, Ellis MJ, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791
13. Di Leo A, Gancberg D, Larsimont D, et al. (2002) HER-2 amplification and topo-isomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8: 1107-1116
14. Di Leo A, Larsimont D, Gancberg D, et al. (2001) HER-2 and topo-isomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 12: 1081-1089
15. Edgerton SM, Moore D 2nd, Merkel D, Thor AD (2003) erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 11: 214-221
16. Elledge RM, Green S, Ciocca D, et al. (1998) HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 4: 7-12
17. Elledge RM, Green S, Pugh R, et al. (2000) Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 89: 111-117
18. Ferreira A, Caceres A (1991) Estrogen-enhanced neurite growth: evidence for a selective induction of Tau and stable microtubules. J Neurosci 11: 392-400
19. Fossati R, Confalonieri C, Torri V, et al. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439-3460
20. French Epirubicin Study Group (2000) Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol 18: 3115-3124
21. Gancberg D, Di Leo A, Cardoso F, et al. (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13: 1036-1043
22. Gong Y, Booser DJ, Sneige N (2005) Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103: 1763-1769
23. Harris LN, Broadwater G, Lin NU, et al. (2006) Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 8: R66
24. Hess KR, Anderson K, Symmans WF, et al. (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24: 4236-4244
25. Hoehn JL, Plotka ED, Dickson KB (1979) Comparison of estrogen receptor levels in primary and regional metastatic carcinoma of the breast. Ann Surg 190: 69-71
26. Hortobagyi GN, Smith TL, Legha SS, et al. (1983) Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1: 776-786
27. Jacquemier J, Penault-Llorca F, Mnif H, et al. (2006) Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-micro-arrays (TMA). Proc Am Soc Clin Oncol 24: abstract 509
28. Järvinen TA, Tanner M, Bärlund M, et al. (1999) Characterization of topo-isomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26: 142-150
29. Jones D, Ghersi D, Wilcken N (2006) Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database Syst Rev 3: CD003368
30. Kataja VV, Colleoni M, Bergh J, ESMO Guidelines Task Force (2005) ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC). Ann Oncol 16(suppl 1): 10-12
31. Knoop AS, Knudsen H, Balslev E, et al. (2005) Retrospective analysis of topoisomerase II alpha amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23: 7483-7490
32. Kuukasjärvi T, Kononen J, Helin H, et al. (1996) Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14: 2584-2589
33. Leclercq G, Heuson JC, Deboel MC, Mattheiem WH (1975) Estrogen receptors in breast cancer: a changing concept. Br Med J 1: 185-189
34. Masood S, Bui MM (2000) Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 30: 259-265
35. McShane LM, Altman DG, Sauerbrei W. et al. (2005) Reporting recommendations for tumour MARKer prognostic studies (REMARK). J Natl Cancer Inst 97: 1180-1184
36. Müller A, Homey B, Soto H, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56
37. Müller V, Witzel I, Lück HJ, et al. (2004) Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 86: 9-18
38. National Comprehensive Cancer Network (2006) Clinical practice guidelines in oncology: breast cancer. Version 2.2006
39. National Institute for Health and Clinical Excellence (NICE) (2006) Advanced breast cancer: diagnosis and treatment. www.nice.org.uk
40. Nielsen TO, Hsu FD, Jensen K, et al. (2004) Immunohistochemical and clinical characterization of the basal-like sub-type of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374
41. Norton L, Massagué J (2006) Is cancer a disease of self-seeding? Nature Med 12: 875-878
42. Osborne CK, Bardou V, Hopp TA, et al. (2003) Role of the estrogen receptor coactivator A1B1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95: 353-361
43. Paik S, Bryant J, Tan-Chiu E, et al. (2000) HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000 92: 1991-1998
44. Pivot X, Asmar L, Buzdar AU, et al. (2000) A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 82: 529-534
45. Pritchard KI, Shepherd LE, O'Malley FP, et al. (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354: 2103-2111
46. Rouzier R, Perou CM, Symmans WF, et al. (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685
47. Rouzier R, Rajan R, Wagner P, et al. (2005) Microtubule-associated protein Tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102: 8315-8320
48. Rubens RD (2001) 7. Management of advanced breast cancer. Int J Clin Pract 55: 676-679
49. Ryberg M, Nielsen D, Osterlind K, et al. (2001) Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol 12: 81-87
50. Singletary SE, Connolly JL (2006) Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 56: 37-47
51. Smid M, Wang Y, Klijn JG, et al. (2006) Genes associated with breast cancer metastatic to bone. J Clin Oncol 24: 2261-2267
52. Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nature Med 12: 895-904
53. Tanner M, Järvinen P, Isola J (2001) Amplification of HER-2/neu and topoisomerase II alpha in primary and metastatic breast cancer. Cancer Res 61: 5345-5348
54. Thor AD, Berry DA, Budman DR, et al. (1998) erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346-1360
55. Umekita Y, Sagara Y, Yoshida H (1998) Estrogen receptor mutations and changes in estrogen receptor and progesterone receptor protein expression in metastatic or recurrent breast cancer. Jpn J Cancer Res 89: 27-32
56. Von Minckwitz G, for the Breast Commission of the German Gynaecological Oncology Working Group (AGO) (2006) Evidence-based treatment of metastatic breast cancer - 2006 recommendations by the AGO Breast Commission. Eur J Cancer 42: 2897-2908
57. Withoff S, Keith WN, Knol AJ, et al. (1996) Selection of a subpopulation with fewer DNA topo-isomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer 74: 502-507
58. Wolff AC, Hammond ME, Schwartz JN, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145
59. Yamamoto N, Watanabe T, Katsumata N, et al. (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16: 2401-2408
60. Zheng WQ, Lu J, Zheng JM, et al. (2001) Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression. Steroids 66: 905-910
61. Zidan J, Dashkovsky I, Stayerman C, et al. (2005) Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93: 552-556